| NCT05571969 | Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors | SUSPENDED | PHASE1 | 2023-02-20 | 2025-12 | 2024-10-01 |
| NCT04796324 | Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. | SUSPENDED | PHASE2 | 2021-03-01 | 2025-11-01 | 2024-12-01 |
| NCT03878849 | Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer | RECRUITING | PHASE2 | 2019-04-15 | 2027-09 | 2027-03 |
| NCT03643107 | Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) | COMPLETED | PHASE2 | 2018-10-17 | 2022-08-01 | 2021-10-01 |
| NCT03562832 | Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP | COMPLETED | PHASE2 | 2018-06-20 | 2024-08-01 | 2024-04-01 |
| NCT03196947 | Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP | TERMINATED | PHASE1, PHASE2 | 2017-06-13 | 2020-01-16 | 2020-01-16 |
| NCT01861496 | Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours | COMPLETED | PHASE1, PHASE2 | 2013-04 | 2021-10 | 2021-10 |